Last updated: February 22, 2026
What is NDC 33342-0274?
NDC 33342-0274 refers to Xenazine (tetrabenazine), a drug approved for the treatment of hyperkinetic movement disorders such as chorea associated with Huntington's disease. It is marketed by Teva Pharmaceuticals. This medication has indications primarily within neurology, with a relatively niche but critical market focus.
Market Overview
Market Size and Penetration
The global neurologic disorder treatment market is valued at approximately USD 8.5 billion in 2023, with rare movement disorders like Huntington's disease constituting a subsection estimated at USD 200 million.[1] Xenazine's market share relies heavily on prescribing patterns, regulatory approvals, and the availability of alternatives.
United States accounts for about 70% of global sales, driven by high diagnosis rates, reimbursement access, and established clinical guidelines.
Competitor Landscape
Key competitors include:
- Deutetrabenazine (Austedo) by Teva—marketed for similar indications
- Valbenazine (Ingrezza) by Neurocrine Biosciences—approved for tardive dyskinesia, with off-label use in Huntington's chorea
- Off-label treatments such as antipsychotics and other VMAT2 inhibitors
Prescribing Trends and Reimbursement
Prescription data indicate approximately 4,000–6,000 patients in the U.S. receive Xenazine annually. Coverage varies with Medicaid, Medicare, and private insurers.
Reimbursement policies tend to favor newer agents like Deutetrabenazine due to dosing convenience and side effect profiles, leading to competitive market pressures for Xenazine.
Price Analysis
Current Price Points
In 2023, the average wholesale price (AWP) per unit (25 mg tablets) is approximately USD 25–30.[2] Daily treatment typically involves 75–100 mg, translating to USD 75–120/day.
Cost Structure and Pricing Strategies
- Wholesale acquisition cost (WAC): USD 20–25 per 25 mg tablet
- Gross margin: ~25-30%
- Pricing is influenced by state Medicaid rebate programs, which often reduce net prices by up to 50%
Price Trends and Projections
Over the past five years, the per-unit pricing of Xenazine has remained relatively stable, with minor increases aligned with inflation and manufacturing cost adjustments. Price erosion owing to generic competition is limited given the drug's patent status and limited generic entries.
Projected Price Developments (2024–2028):
| Year |
Expected Price Range per Tablet |
Key Drivers |
| 2024 |
USD 23–27 |
Patent expiration, generic entry pressure |
| 2025 |
USD 20–24 |
Increased generic penetration |
| 2026 |
USD 18–22 |
Market share shift, biosimilars potential |
| 2027 |
USD 16–20 |
Generic saturation, utilization decline |
| 2028 |
USD 15–18 |
Market stabilization, biosimilar competition |
Factors Impacting Price Trajectories
- Patent protections: Patents lapse in 2024, opening the market to generics.
- Regulatory decisions: FDA approvals or restrictions on generics.
- Market consolidation: Mergers or agreements affecting pricing power.
- Off-label use growth: Expansion into other therapeutic areas could sustain demand.
Revenue Projections
Based on current prescribing rates and assumed price declines, annual revenue could decrease from USD 300 million in 2023 to around USD 150 million by 2028. Generic entry will likely accelerate price declines and reduce margins.
Risks and Opportunities
- Patent expiration introduces risk of generic competition, pressuring prices.
- Market expansion through new indications could offset volume declines.
- Pricing pressures from payers and biosimilars may further suppress prices.
Key Takeaways
- Xenazine's current market is niche but steady, with US dominance.
- Prices are industry-standard at USD 25–30 per tablet, with expected declines post-patent expiration.
- Market share is threatened by newer agents like deutetrabenazine, though Xenazine remains a key treatment option.
- Projections anticipate a steady decline in price, aligning with generic market entry over the next five years.
- Revenue will likely diminish unless new indications or formulations are introduced.
FAQs
Q1: When does patent expiration for Xenazine occur?
A1: Patent expiration is scheduled for late 2024, enabling generic competition.
Q2: How will generic entry impact prices?
A2: Prices are expected to decline by 10-30% within the first year post-generic entry, with further erosion over time.
Q3: What are the main competitors to Xenazine?
A3: Deutetrabenazine (Austedo) and Valbenazine (Ingrezza) are primary competitors, offering similar efficacy with different side effect profiles.
Q4: Are there any regulatory barriers to generic entry?
A4: No significant barriers; however, complex manufacturing processes for VMAT2 inhibitors may impact timing.
Q5: Which markets beyond the US are relevant?
A5: Europe, Canada, and select Asian markets are increasingly adopting Huntington's disease treatments, but market size remains smaller compared to the US.
References
[1] MarketWatch. (2023). Neurodegenerative disorders market size and segmentation.
[2] GoodRx. (2023). Xenazine pricing data.
